immunotherapy

Dr Rashem Mothilal explains how the registration aims to expand access to immunotherapy for patients with recurrent or metastatic…

UK-led phase III trial reports similar disease control at 12 months versus two years of immunotherapy for inoperable late-stage…

According to GlobalData’s Drugs Database, blood cancers account for over half of all CAR-Ts in the active pipeline* and make up…

Sintilimab, marketed as TYVY (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody…

Older adults aged 60 years and above accounted for almost 87 per cent of the diagnosed incident cases of bladder cancer in the 8MM…

Merck faces setback as Keytruda combination trials fail to expand cancer treatment ahead of patent loss

The International Agency for Research on Cancer (IARC) forecasts a 58 per cent surge in GI cancer cases by 2040 globally 

KEYTRUDA is now approved for 14 indications across eight tumour types in India

The technology enables the screening of substantial amounts of cancer samples without requiring fresh biopsies or biological…

Imfinzi is the only immunotherapy-based combination treatment option in India that offers significantly improved survival rates in…